


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 20 has been cancelled.

1. (Previously presented): A compound of the formula (I):



wherein

R₁, R₂, R₃, and R₄ are, independently of one another, alkyl residues with 1 to 6 carbon atoms;

or a physiologically tolerated salt thereof,

or an ester, ether, complex, or adduct thereof,

or a stereoisomeric form of:

a compound of formula (I) as described above,

or a physiologically tolerated salt of a compound of formula (I) as described above,

or an ester, ether, complex, or adduct of a compound of formula (I) as described above

or a tautomeric form of:

a compound of formula (I) as described above,

or a physiologically tolerated salt of a compound of formula (I) as described above,
or an ester, ether, complex, or adduct of a compound of formula (I) as described above.

2. (Previously presented): The compound of formula (I) as claimed in claim 1, wherein one, two, three, or all of R₁ to R₄ are butyl residues, and wherein any of the butyl residues may be straight-chain or branched,

or a physiologically tolerated salt thereof,
or an ester, ether, complex, or adduct thereof,
or a stereoisomeric form of:

the compound of formula (I) as described above in this claim,
or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,
or an ester, ether, complex, or adduct of the compound of formula (I) as described above in this claim,

or a tautomeric form of:

the compound of formula (I) as described above in this claim,
or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,
or an ester, ether, complex, or adduct of the compound of formula (I) as described above in this claim.

3. (Previously presented): The compound of formula (I) as claimed in claim 1, wherein R₁ to R₄ are, in any combination, three butyl residues and one propyl residue, and wherein any of the alkyl residues may be straight-chain or branched,

or a physiologically tolerated salt thereof,
or an ester, ether, complex, or adduct thereof,
or a stereoisomeric form of:

the compound of formula (I) as described above in this claim,
or a physiologically tolerated salt of the compound of formula (I) as
described above in this claim,
or an ester, ether, complex, or adduct of the compound of formula (I) as
described above in this claim,

or a tautomeric form of:

the compound of formula (I) as described above in this claim,
or a physiologically tolerated salt of the compound of formula (I) as
described above in this claim,
or an ester, ether, complex, or adduct of the compound of formula (I) as
described above in this claim.

4. (Previously presented): The compound of formula (I) as claimed in claim 1,
wherein R₁ to R₄ are, in any combination: two butyl and two propyl residues, or one
butyl, one pentyl, one ethyl, and one propyl residue, and wherein any of the butyl,
propyl, or pentyl residues may be straight-chain or branched,

or a physiologically tolerated salt thereof,
or an ester, ether, complex, or adduct thereof,
or a stereoisomeric form of:

the compound of formula (I) as described above in this claim,
or a physiologically tolerated salt of the compound of formula (I) as
described above in this claim,
or an ester, ether, complex, or adduct of the compound of formula (I) as
described above in this claim,

or a tautomeric form of:

the compound of formula (I) as described above in this claim,
or a physiologically tolerated salt of the compound of formula (I) as
described above in this claim,

or an ester, ether, complex, or adduct of the compound of formula (I) as described above in this claim.

5. (Previously presented): The compound of formula (I) as claimed in claim 1, wherein R_1 to R_4 are, in any combination: four butyl residues or two butyl, one propyl and one pentyl residue, and wherein any of the alkyl residues may be straight-chain or branched,

or a physiologically tolerated salt thereof,
or an ester, ether, complex, or adduct thereof,
or a stereoisomeric form of:

the compound of formula (I) as described above in this claim,
or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,
or an ester, ether, complex, or adduct of the compound of formula (I) as described above in this claim,

or a tautomeric form of:

the compound of formula (I) as described above in this claim,
or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,
or an ester, ether, complex, or adduct of the compound of formula (I) as described above in this claim.

6. (Original): A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 1.

7. (Original): A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 2.

8. (Original): A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 3.

9. (Original): A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 4.

10. (Original): A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 5.

11. (Previously presented): A compound of the formula (I), or a physiologically tolerated salt or an ester, ether, complex, or adduct thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1, obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.

12. (Previously presented): A compound of the formula (I), or a physiologically tolerated salt or an ester, ether, complex, or adduct thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 2, obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.

13. (Previously presented): A compound of the formula (I), or a physiologically tolerated salt or an ester, ether, complex, or adduct thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 3, obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.

14. (Previously presented): A compound of the formula (I), or a physiologically tolerated salt or an ester, ether, complex, or adduct thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 4, obtainable by cultivation of Streptomyces sp.

ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.

15. (Previously presented): A compound of the formula (I), or a physiologically tolerated salt or an ester, ether, complex, or adduct thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 5, obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.

16. (Previously presented): A process for the production of a compound of formula (I), or a salt or an ester, ether, complex, or adduct thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1, comprising

cultivating Streptomyces sp. ST 101396 (DSM 13309) or one of its variants or mutants,

isolating and purifying one or more target compounds, and

optionally converting said target compound into a physiologically tolerated salt or derivative.

17. (Original): The process as claimed in claim 16, wherein the cultivation is carried out at a temperature in the range between about 20°C and about 35°C and a pH in the range between about 5 and about 8.

18. (Previously presented): A pharmaceutical composition comprising an effective amount of at least one compound of formula (I), or a physiologically tolerated salt or an ester, ether, complex, or adduct thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1, and a pharmaceutically acceptable carrier.

19. (Previously presented): A method for reducing the activity of a neurotensin receptor comprising administering to a patient in need thereof at least one compound of formula (I), or a physiologically tolerated salt or an ester, ether, complex, or adduct thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1.

20 (Cancelled)

21 (Previously presented): A method for the production of a pharmaceutical composition, comprising mixing at least one compound of formula (I), or a physiologically tolerated salt or an ester, ether, complex, or adduct thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1, and suitable excipients and/or carriers, and converting the mixture into a suitable dosage form.

22 (Previously presented): Isolated Streptomyces species ST 101396 (DSM 13309).